About Anthem Biosciences IPO
The IPO is an Offer for Sale (OFS) and comprises stake sale aggregating up to Rs 350 crores each by Ganesh Sambasivam and K Ravindra Chandrappa who are promoter selling shareholders. Up to Rs 1,325 crores will be offloaded by Viridity Tone LLP and up to Rs 320 crores by Portsmouth Technologies LLC (Investor Selling Shareholders).
It also includes stake sales of Rs 320 crores each by Malay J Barua, Rupesh N Kinekar and Satish Sharma, up to Rs 80 crore by Prakash Kariabettan and up to Rs 10 crore by K Ramakrishnan.
About Anthem Biosciences
Anthem’s business comprises Contract Research, Development and Manufacturing Organization (CRDMO) services and the manufacture and sale of specialty ingredients. It offers a comprehensive, integrated and highly customizable range of CRDMO services across the New Chemical Entity (NCE) and New Biological Entity (NBE) lifecycles.
The company claims to have a strong presence across various modalities, such as RNAi, ADC, peptides, lipids and oligonucleotides, and manufacturing techniques, such as flow chemistry, enzymatic processes, biocatalysis and fermentation, offering a broad range of technology capabilities for drug development.
It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.
Ajay Bhardwaj (Chairman, MD & CEO), Ganesh Sambasivam (Whole-time Director and Chief Scientific Officer), K Ravindra Chandrappa (Whole-time Director and Chief Operating Officer) and Ishaan Bhardwaj (Vice President) are the Promoters of the company.The company, which was incorporated in 2006, has two operational manufacturing facilities in India, Unit I (Bommassandra) and Unit II (Harohalli), both in Karnataka, with an aggregate annual custom synthesis capacity of 270 kL and fermentation capacity of 142 kL, as of March 31, 2025.According to the RHP, the company is in the process of expanding its custom synthesis capacity at Unit II (Harohalli) by 130 kL as well as expanding its custom synthesis capacity by 25kL and fermentation capacity by 40kL by constructing Unit III (Neoanthem Lifesciences Private Limited, wholly-owned Subsidiary), both expected to be fully operational by the first half of Fiscal 2026.
Post-expansion activities, the aggregate annual custom synthesis capacity and fermentation capacity is expected to increase to 425 kL and 182 kL, respectively. The fermentation capacity of 182 kL is expected to be more than six times the capacity of the second largest player in this industry, according to the F&S Report.
Anthem Biosciences financials
Its revenue from operations increased by 30% to Rs 1,844 crores in FY25 from Rs 1,419 crores in FY24. The PAT for the year ended March 31, 2025 was Rs 451 crores, a jump of 22.86% over FY24.
Sai Life Sciences Limited, Syngene International Limited, Cohance Lifesciences Limited, (Formerly Suven Pharmaceuticals) and Divi’s Laboratories Limited are the listed peers of Anthem Biosciences, as per its RHP.
Anthem Biosciences lead managers
The Book Running Lead Managers to the offer are JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited.
The equity shares are proposed to be listed on BSE and NSE.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
